Home Top Movers Akebia Therapeutics Inc. (AKBA) stock surged in the premarket trading session; here’s...

Akebia Therapeutics Inc. (AKBA) stock surged in the premarket trading session; here’s why

In the premarket trading session, Akebia Therapeutics Inc. (AKBA) stock had surged by 8.44% to the price of $3.47 at the time of writing. AKBA stock previously closed the session at $3.20 gaining 0.95%. The AKBA stock volume traded for 2.17 million shares. The average 3-month volume of trade is 5.71 million shares. In the past year, AKBA stock slumped by -60.20%. While in the past week, the shares moved up by 7.74%. Furthermore, Akebia Therapeutics Inc. is currently valued in the market at $492.83 million and has 145.16 million outstanding shares.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

About Akebia Therapeutics Inc.

Akebia Therapeutics, Inc., a biopharmaceutical company which specifically focuses on the design, development and marketing of therapeutics that are based on renal treatment of kidney diseases for patients. Akebia’slead investigational candidate is an oral therapy which is being developed and is currently in the Phase III level study. This therapeutic product is known as vadadustat and the phase III study is being done for anemia’s treatment which occurs in dialysis-dependent and non-dialysis dependent adult patients because of chronic kidney disease (CKD). Another product of the company is known as Auryxia which is used to control the serum phosphorus levels in adult patients through the drug’s ferric citrate properties. These patients have CKD and are on dialysi. Furthermore, the treatment is purposed for iron deficiency anemia in patients that have CKD but are not on dialysis.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Read More

About Vatadsudat’s clinical development

Akebia Therapeutics, Inc. has given the development and commercialization rights to Otsuka Pharmaceutical Co. Ltd. (as a collaboration partner) for the vadadustat in the United States as well as certain foreign countries and regions like the European Union, Russia, China, Australia, Canada, the Middle East, and other countries. Akebia Therapeutics, Inc. has given the development and commercialization rights to Mitsubishi Tanabe Pharma Corporation (as a collaboration partner) for the vadadustat in Japan and other Asian countries. The company has partnered with Janssen Pharmaceutica licensing and research agreement of the development and commercialization of hypoxia-inducible factor prolull hydroxylase targeted compounds worldwide,

Announcing the date for 1st Quarter 2021 results release

On 28th April 2021, Akebia decided to release the financial result of the 1st Quarter 2021 on the date of 10th May 2021 before the financial markets are opened; the conference call will be held on 9:00 am ET.

Publishing of Vadadustat’s Phase III result on NEJM

Similarly, on 28th April 2021, the therapeutics company announced that its results for the global phase 3 study of the Vadadustat clinical program is being published in New England Journal of Medicine (NEJM). Vadadustat is used for the treatment of anemia due to CKD (chronic kidney disease). The phase III program’s purpose was to study the efficacy and safety of the investigational candidate in adult patients that anemia due to CKD, both on dialysis or not on dialysis.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Vadadustatwas submitted by AkebiaTherapeutics Inc. for FDA approval under a New Drug Application (NDA) in the late march 2021. There were 7500 patients that participated in the program. The study’s Phase III program was aimed to see cardiovascular safety and hematological efficacy results of phase 3 program and now the publishing enhances the relevance of vadadustat’s clinical development.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Palatin Technologies Inc. (PTN) stock rises during pre-market trading. What has been happening lately?

Palatin Technologies Inc. (NASDAQ: PTN) stock declined by 1.16% the last close whereas the PTN stock price gains by 3.91% in the pre-market trading...

Smith Micro Develops Inc. (SMSI) stock soars during current market trading. Here’s to know why?

Smith Micro Develops Inc. (NASDAQ: SMSI) stock surged by 2.39% during the current market trading session. Smith Micro creates software that simplifies and improves...

Drive Shack Inc. (DS) stock soars during after-hour trading, followed by no recent update

Drive Shack Inc. (NASDAQ: DS) stock declined by 3.94% at last close while the DS stock-price surged by 7.38% in the after-hour session. Drive...

SPX Flow Inc. (FLOW) stock surged during current market. Here’s why the stock is sky-rocketing?

SPX Flow Inc. (NASDAQ: FLOW) stock gained by 24.24% in the current market trading session. SPX FLOW, based in Charlotte, works to make the...

Platinum Group Metal Ltd. (PLG) stock surges during after-market trading. Here’s to know what’s happening?

Platinum Group Metal Ltd. (NASDAQ: PLG) stock declined by 8.54% at last close whereas the PLG stock price gains by 7% in the after-market...

TD Holdings Inc. (GLG) stock gains during current market trading. Here’s the recent update

TD Holdings Inc. (NASDAQ: GLG) stock gains by 5.01% in the current market trading session. TD Holdings, Inc. is a service provider in China...

Palatin Technologies Inc. (PTN) stock rises during pre-market trading. What has been happening lately?

Palatin Technologies Inc. (NASDAQ: PTN) stock declined by 1.16% the last close whereas the PTN stock price gains by 3.91% in the pre-market trading...

NeuroMetrix Inc. (NURO) stock plunged during pre-market. Let’s find out why?

NeuroMetrix Inc. (NASDAQ: NURO) stock gained by 18.89% at last close while the NURO stock price losses by -4.12% in the pre-market trading session....

Related News

Veoneer Inc. (VNE) stock shows massive gains during pre-market. What’s driving it high?

Veoneer Inc. (NASDAQ: VNE) stock decline by 1.82% at the last close whereas the VNE stock price gains by 55.19% in the pre-market trading...

AnPac Bio-Medical Sciences Inc. (ANPC) stock soars during pre-market. Here’s what you should know?

AnPac Bio-Medical Sciences Inc. (NASDAQ: ANPC) stock declined by 4.98% at last close however the ANPC stock price gains by 6.96% in the pre-market...

Endeavour Silver Corp. (EXK) stock surged during pre-market trading. Here’s what you should know?

Endeavour Silver Corp. (NASDAQ: EXK) stock declined by 4.97% at the last close whereas the EXK stock price gains by 3.56% in the pre-market...

Here is why Amneal Pharmaceuticals Inc (AMRX) stock soared on Monday?

Amneal Pharmaceuticals Inc. (AMRX) shares rose 7.18% in after-hours on Monday, July 19, 2021, and closed at $4.63 per share. Earlier in the morning,...

Why Applied DNA Sciences Inc. (APDN) stock had a bad Friday?

Applied DNA Sciences Inc. (APDN) shares fell 5.27% in after-hours on Friday, July 16, 2021, at $5.03 per share. Earlier, APDN's stock lost 2.93%...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam